Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Non-Diabetic HFrEF Patients
NCT06632561Phase 4Completed
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Empagliflozin Arm with Placebo Arm (2 arms). Primary endpoints: Left Ventricular Volumes at 6 months and Left Ventricular Ejection Fraction at 6 months. Started Jul 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06632561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632561.